Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

Children's Oncology Group

Status

Completed

Conditions

Leukemia

Treatments

Other: laboratory biomarker analysis

Other: flow cytometry

Genetic: western blotting

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT01150058

NCI-2011-02241 (Registry Identifier)

AAML10B19 (Other Identifier)

COG-AAML10B19 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

PURPOSE: This research study is studying drug biomarkers in cell samples from patients with acute myeloid leukemia.

Full description

OBJECTIVES:

To determine, in vitro, the cytotoxic activity of novel CD33-targeting immunoconjugate agents in cell samples from patients with acute myeloid leukemia (AML).
To define the characteristics of AML cells responding to or resisting these agents.

OUTLINE: Cell samples are thawed and used for in vitro studies to determine the cytotoxic activity of novel CD33-targeting immunoconjugate agents, including gemtuzumab ozogamicin, for genotyping characterization by flow cytometry-based assays and/or western blot, and colony-forming cell assays.

Enrollment

40 patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: